Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. - Wikidata - wikimedia - TriplyDB

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

http://www.wikidata.org/entity/Q34576734

about

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential Metabolic correction in the management of diabetic peripheral neuropathy: improving clinical results beyond symptom control Pathways in the diagnosis and management of diabetic polyneuropathy Ranirestat for the management of diabetic sensorimotor polyneuropathy Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial Safety and efficacy of an add-on therapy with curcumin phytosome and piperine and/or lipoic acid in subjects with a diagnosis of peripheral neuropathy treated with dexibuprofen Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function.Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway.Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin.Treatment of diabetic sensory polyneuropathy.A 41-year-old man with polyarthritis and severe autonomic neuropathy.Painful diabetic neuropathy: advantage of novel drugs over old drugs?Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities.Therapeutic interventions and oxidative stress in diabetes Diabetic neuropathy part 1: overview and symmetric phenotypes Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy.The Association between Serum GGT Concentration and Diabetic Peripheral Polyneuropathy in Type 2 Diabetic Patients.Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases.Prevalence and correlates of diabetic peripheral neuropathy in a Saudi Arabic population: a cross-sectional study.Effect of rosuvastatin on diabetic polyneuropathy: a randomized, double-blind, placebo-controlled Phase IIa study.Systematic review of treatments for diabetic peripheral neuropathy.Nutritional supplements and their effect on glucose control.Proficiency of nerve conduction using standard methods and reference values (Cl. NPhys Trial 4)Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy.Effects of aspirin & simvastatin and aspirin, simvastatin, & lipoic acid on heme oxygenase-1 in healthy human subjects.Alpha lipoic acid attenuates radiation-induced thyroid injury in rats.Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice.Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy.Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series.Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms.Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury.Role of Drp1, a key mitochondrial fission protein, in neuropathic pain.Update on the management of diabetic polyneuropathies.Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.(R)-(+)-α-lipoic acid protected NG108-15 cells against H₂O₂-induced cell death through PI3K-Akt/GSK-3β pathway and suppression of NF-κβ-cytokines.

P2860

Q21285063-CF453814-1FCE-4CA9-BB4E-18250F8E1C12 Q22241837-EA652F5E-C035-40E1-B039-307B2DF3F17D Q24658099-FB4A5BF2-8DEB-44FD-A78A-4ABE8F671292 Q26852079-FCF41CF7-C3AE-4A06-B312-DE110A41E53B Q28082465-3EB23257-C871-4F1D-A77F-109CEA194E72 Q28241270-05C8867E-011D-4F5B-8CBA-3EC625775071 Q28304712-DFA26982-5533-47B6-8B92-2B53F6C3536B Q28385294-0685D75A-3904-4051-AFD8-C766856C22FB Q28569638-AF1D978F-1865-4905-BB3E-ED1D03E46561 Q28820780-FCBA753F-DD36-48EF-93BD-2930A269CA4C Q30239828-ED523494-59CA-4046-B182-B634E0EFA8F4 Q30432705-558671FA-FE9C-42F9-8318-6C7B75000DC0 Q30537158-6C1FE524-50A8-43A2-86D1-F8CAB5754E8C Q33393882-91B0ECD2-ED97-4B07-BE24-E1CC9A60F3B6 Q33408182-43C37206-A56D-4222-874B-ABB23A5CA551 Q33610824-E3C460D4-79E8-4867-BC4B-AC99F6A824B8 Q33668501-545E6D49-3E2D-4E61-88FF-AB45F78E7223 Q33870395-4513C8F2-39B8-4518-A46F-449EDEAA78BB Q33878023-8575FBC5-FF5A-4437-B1B9-FD7A5523A7BA Q33887571-900DD38B-695F-4C86-A085-919CC0F3442C Q33904484-5D8B8C10-C9BD-439E-804E-1EACF9444E04 Q34012029-65D3564F-E2CC-4C83-A97D-237A946BBFC0 Q34128919-01DE6D92-248D-4801-8B56-19629BDD5B6C Q34156106-84639C87-4840-4A9F-8993-7A7EEF58B900 Q34161497-5C68024A-F5FD-4A05-BB6C-841E19D7DE70 Q34162991-5FC0F180-9493-46D5-BC2F-192C0FF170EC Q34214542-3E953DB2-C700-4829-9E7B-55EE975AADCB Q34218901-3EC476E3-2983-4BED-812A-E388E306FA54 Q34255336-5D2430B2-C416-4E7B-B18D-7D8612289168 Q34525368-76AD67E9-9999-4A1C-B00C-500A117D59F4 Q34603050-761A9870-BBAC-4912-A5C9-FF358E3A44E5 Q34631169-94F07119-E04D-4BFE-81A9-0975E7CEABB3 Q34645584-CE54BF91-4F24-4B84-8D22-97579585591A Q34646991-71B53D56-A960-41B7-8800-6FDF4FA72540 Q34685307-CD3E1F07-820C-41CC-A1D1-6AAC949EE7A4 Q34730353-E5418EA2-8351-48FE-A4F0-5DB199A8EBB6 Q35168122-86CEDD88-83D0-41C3-9DED-665208BB8817 Q35178801-560CC8A4-AE9C-4C22-BBE6-C30A2398FABA Q35179957-7D091A27-627B-4BFC-B38A-71FEDE01D6DD Q35357443-11C02902-B969-468E-A921-C67DA3E5ACEE

P2860

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

http://www.wikidata.org/entity/Q34576734

description

2006 nî lūn-bûn

@nan

2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@ast

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@en

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@nl

type

label

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@ast

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@en

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@nl

prefLabel

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@ast

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@en

Oral treatment with alpha-lipo ...... europathy: the SYDNEY 2 trial.

@nl

P1433

Q34576734-C290BAEA-1D78-47B1-9476-3F48E3709756

P1476

Q34576734-7E60151E-EA43-4D13-A9E4-1903CC930F32

P2093

Q34576734-08F01E4D-C094-4D1E-9804-C3F89CF9F306

Q34576734-224FC560-3DCF-406F-91B4-619029DA4F7D

Q34576734-322E0F21-9353-4F6C-844B-84AFB6244CFF

Q34576734-38DCF870-BE2A-4C6B-BB26-C015DCE6D446

Q34576734-A16E0BAA-36E8-46A0-84C7-92C737555E24

Q34576734-C0C1BE7B-FF2E-45E8-8FC2-812775B05729

Q34576734-C63B9021-B046-445E-B208-609319FF6D1C

Q34576734-E40B21C5-691B-4DE3-B74C-B8837FD92246

Q34576734-E42B2170-6553-4C53-9CBB-E9F2F345CAA0

Q34576734-F526A975-4F45-48BB-9FB6-ADEAC443CB64

P304

Q34576734-D3DB9CD0-BE25-48B1-A0D6-9D4AD3C546A6

P31

Q34576734-5EE5B544-99B8-480D-9C0F-C6C1FAFB7735

P356

Q34576734-FBAA0CEE-C773-441A-B215-C769CDE91313

P407

Q34576734-251DF501-A499-4B68-B4AD-2D312F7BE73D

P433

Q34576734-015B6690-1237-47FE-8D22-8838C2103284

P478

Q34576734-379EDBA9-5BB9-411C-8DCB-547B439F6398

P50

Q34576734-003F87AE-A964-4CAE-B57A-E565A6FBBAAA

Q34576734-7D34EB24-0B70-4FA5-A245-9ABD5FFCF28C

P577

Q34576734-1D9DE6AF-2643-4AD7-92A8-186E4ED4C793

P5875

Q34576734-2BA7162D-9ACD-44B3-B5DE-BF59D5C78F3A

P698

Q34576734-AC7E828C-5A90-4A17-8603-3C4ED2CD2F5A

P356

P1433

P1476

Oral treatment with alpha-lipo ...... neuropathy: the SYDNEY 2 trial

@en

P2093

Alexey Barinov

http://www.w3.org/2001/XMLSchema#string

Dan Ziegler

http://www.w3.org/2001/XMLSchema#string

Irina Gurieva

http://www.w3.org/2001/XMLSchema#string

Itamar Raz

http://www.w3.org/2001/XMLSchema#string

Joachim Maus

http://www.w3.org/2001/XMLSchema#string

Maria Novosadova

http://www.w3.org/2001/XMLSchema#string

Peter J Dyck

http://www.w3.org/2001/XMLSchema#string

Phillip A Low

http://www.w3.org/2001/XMLSchema#string

Rustem Samigullin

http://www.w3.org/2001/XMLSchema#string

Ullrich Munzel

http://www.w3.org/2001/XMLSchema#string

P304

2365-2370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC06-1216

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Nikolay N Yakhno

Alexander S Ametov

P577

2006-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6729916

http://www.w3.org/2001/XMLSchema#string

P698

17065669

http://www.w3.org/2001/XMLSchema#string